Gates MRI and SII Partner to Manufacture Novel TB Vaccine
Source:Indian Express ↗
কেন এটি গুরুত্বপূর্ণ
Tuberculosis remains a critical public health issue and the leading infectious cause of death globally, with India bearing the highest national burden. The development of a new vaccine candidate after over a century is highly relevant for both GS2 (Health Policy/Governance) and GS3 (S&T development, indigenous manufacturing, and biotech). It showcases the intersection of global philanthropic funding, cutting-edge vaccine development, and India's unparalleled capability to manufacture high-quality, affordable vaccines at scale.
সারসংক্ষেপ
The Gates Medical Research Institute (Gates MRI) and Serum Institute of India (SII) have partnered to manufacture and scale M72/AS01E, a breakthrough tuberculosis (TB) vaccine candidate currently in Phase 3 trials. If approved, this would be the first new TB vaccine in over a century. Under the agreement, GSK (the original developer) will supply the adjuvant AS01E, while SII will invest over $100 million to build manufacturing capacity, highlighting India's key role as a global pharmaceutical manufacturing hub.
মূল বিষয়
- Gates Medical Research Institute (Gates MRI) and Serum Institute of India (SII) have partnered for technology transfer and manufacturing of the novel TB vaccine candidate M72/AS01E.
- If successful, M72/AS01E will be the first new vaccine developed for tuberculosis in more than a century (since BCG in 1921), targeting the world's leading infectious cause of death.
- SII will invest over $100 million of its own resources to strengthen manufacturing capacity and readiness for potential future supply ahead of the Phase 3 trial outcomes.
- Phase 3 trials, funded by the Gates Foundation and Wellcome, completed full enrollment of 20,000 participants in April 2025 across five countries: South Africa, Kenya, Malawi, Zambia, and Indonesia.
- In prior Phase 2b trials conducted by GSK (the original developer providing the AS01E adjuvant), the vaccine candidate showed approximately 50% protection against progression to active pulmonary TB in TB-infected, HIV-negative adults over a three-year period.
- According to WHO estimates, a TB vaccine with this efficacy profile could prevent 76 million new TB cases, save 8.5 million lives, and prevent $41.5 billion in economic damages to affected households over 25 years.
গুরুত্বপূর্ণ শব্দ
M72/AS01E
A breakthrough tuberculosis vaccine candidate currently in Phase 3 trials. Designed for adolescents and adults, it consists of an M72 recombinant antigen and GSK's proprietary AS01E adjuvant to stimulate a strong immune response.
UPSC context
GS Paper III: Science & Technology. Tested for developments in healthcare, vaccine technology, and India's role in global clinical advancements.
BCG (Bacillus Calmette-Guérin) Vaccine
A live attenuated vaccine developed in 1921, currently the only licensed vaccine for tuberculosis. It effectively prevents severe childhood forms of TB but provides limited protection against adult pulmonary TB.
UPSC context
GS Paper II: Social Sector (Health). Tests core knowledge of immunization programs, infectious diseases, and healthcare challenges like TB.
Serum Institute of India (SII)
An Indian biotechnology firm and the world's largest vaccine manufacturer by volume. It plays a pivotal role in producing affordable, WHO-prequalified vaccines, driving global immunization and public health campaigns.
UPSC context
GS Paper III: Indigenization of technology. Relevant to India’s pharmaceutical leadership, industrial capacity, and global health diplomacy.
Gates Medical Research Institute (Gates MRI)
A non-profit biotech organization and affiliate of the Bill & Melinda Gates Foundation. It sponsors medical research and clinical trials for diseases of high global burden, particularly tuberculosis and malaria.
UPSC context
GS Paper II: Role of NGOs and philanthropy. Tests understanding of public-private partnerships and international financing in health security.
GSK (GlaxoSmithKline)
A global biopharmaceutical company that originally developed the M72 TB vaccine candidate. It maintains involvement in the program by supplying its proprietary adjuvant, AS01E, to boost immune efficacy.
UPSC context
GS Paper III: Intellectual property rights and technology transfer. Evaluates pharmaceutical innovation and collaborative public-private global health models.
Wellcome Trust (Wellcome)
A UK-based charitable foundation focused on health research. Along with the Gates Foundation, it co-funds the landmark Phase 3 clinical trial of the M72/AS01E TB vaccine candidate.
UPSC context
GS Paper II: Health and development. Tests the role of global philanthropic funding in advancing scientific research for neglected tropical diseases.
প্রিলিমস ফাঁদ
The BCG vaccine is prepared from a weakened strain of human tuberculosis bacteria (Mycobacterium tuberculosis).
BCG is actually derived from Mycobacterium bovis (bovine TB). UPSC frequently tests whether candidates confuse bovine and human pathogen strains.
সংযুক্ত স্থির ধারণা
How do vaccine platforms differ and what role do adjuvants play?
- Live-Attenuated Vaccines: Uses weakened live pathogens (e.g., BCG, MMR) to trigger robust, long-lasting immunity, but poses safety risks for immunocompromised individuals.
- Subunit Vaccines: Uses only specific fragments (proteins/sugars, like the M72 antigen) to trigger targeted immunity, minimizing side effects but requiring adjuvants.
- Adjuvant Function: Chemical/biological agents (like AS01E) added to vaccines to amplify and direct the host immune response, critical for subunit vaccines.
What is WHO's definition of TB elimination versus India's national targets?
- WHO Elimination Threshold: Defined epidemiologically as reducing the incidence of tuberculosis to less than 1 notified case of all forms per million population per year.
- India's Target Year: Targeted TB elimination by 2025 under the National TB Elimination Programme (NTEP), five years ahead of the UN SDG 3.3 target of 2030.
- Global Burden Share: India still accounts for approximately 25% of all global TB cases and 28% of global TB-related deaths.
আন্তঃবিষয় প্যাটার্ন
Biodiversity & Global Vaccine Supply Chains
Saponin extracts (QS-21) from the Chilean soapbark tree underline how critical vaccine adjuvant supply chains depend directly on forest biodiversity conservation.
Voluntary Tech Transfer vs TRIPS
The Gates-SII partnership demonstrates how voluntary technology transfers bypass contentious WTO TRIPS compulsory licensing disputes to deliver affordable medical countermeasures.
UPSC may test the biological differences between BCG and subunit vaccines, alongside India's epidemiological TB elimination metrics.
সংযুক্ত PYQ · 3
সংযুক্ত PYQ · 3
- 2020PrelimsGS1
What is the importance of using Pneumococcal Conjugate Vaccines in India? 1. These vaccines are effective against pneumonia as well as meningitis and sepsis. 2. Dependence on antibiotics that are not effective against drug-resistant bacteria can be reduced. 3. These vaccines have no side effects and cause no allergic reactions. Select the correct answer using the code given below:
- 2022MainsGS3
What is the basic principle behind vaccine development ? How do vaccines work? What approaches were adopted by the Indian vaccine manufacturers to produce COVID-19 vaccines ?
- 2024MainsGS2
In a crucial domain like the public healthcare system the Indian State should play a vital role to contain the adverse impact of marketisation of the system. Suggest some measures through which the State can enhance the reach of public healthcare at the grassroots level.
